Search

PSR B1259-63 is a g-ray binary system, where the compact object is a pulsar. The system has an orbital period of 1236.7 days and shows peculiar g-ray flares (in 100MeV–300 GeV) after its periastron time. We analyzed the Fermi-LAT observation of PSR B1259-63 during its latest periastron passage, as well as its previous three periastrons. The bright GeV flares started about 60 days after the periastron epoch in 2021. This delay is larger than that around the 2017 periastron and much larger than earlier periastrons. The delay of the GeV flux peak time in each periastron passage is apparent in our results. We discussed the possible origin of this delay and made a prediction of the GeV flux peak time in next periastron passage, based on observation of the previous delays. [ABSTRACT FROM AUTHOR]

The article presents a retrospective cohort study on the influence of body composition on renal function in patients with coronary artery disease (CAD). Topics discussed include analysing the effect of renal functions on death in CAD patients, detection of influence of renal insufficiency on mortality of CAD in body composition including body mass index (BMI), body fat and lean mass index, and issues related to obesity.

Background: Whether body composition is associated with the N-terminal pro-B-type natriuretic peptide (NTproBNP) level and its prognostic performance in acute coronary syndrome (ACS) remains unknown. We aimed to investigate the influence of body composition on the NT-proBNP level and its prognostic performance among ACS patients. Methods: In total, 1623 ACS patients with NT-proBNP data were enrolled. Percent body fat and lean mass index were estimated using the Clínica Universidad de Navarra--Body Adiposity Estimator equation. Patients were divided into three groups according to the tertiles of sex-specific body mass index, percent body fat, or lean mass index. The endpoints were death from any cause and cardiovascular death. Results: Body mass index was inversely correlated with NT-proBNP levels (β = -0.036, P = 0.003). Lean mass index, but not percent body fat, was inversely associated with NT-proBNP levels (β of lean mass index = -0.692, P = 0.002). During a median follow-up of 23 months, 161 all-cause deaths occurred, and of these, 93 (57.8 %) were attributed to cardiovascular causes. Multivariate Cox analysis showed that the NT-proBNP level independently predicted all-cause mortality or cardiovascular death in the lower body mass index, lean mass index, and percent body fat groups. However, the prognostic performance of NT-proBNP was attenuated in patients with high body mass index, lean mass index, and percent body fat. In the subgroup of patients with diabetes, inverse associations between NT-proBNP levels and body mass index or body composition were not observed. In addition, the negative influence of high body mass index and body composition on the prognostic performance of the NT-proBNP level appeared to be attenuated. Conclusions: Body mass index and lean mass index, but not percent body fat, are inversely associated with NTproBNP levels. The prognostic performance of this biomarker may be compromised in patients with high body mass index, percent body fat, or lean mass index. Additionally, the influence of body composition on the NT-proBNP level and its prognostic performance might be attenuated in diabetic patients with ACS. [ABSTRACT FROM AUTHOR]

The aim of the present review was to investigate the association between the use of oral bblockers and prognosis in patients with acute myocardial infarction (AMI) who underwent percutaneous coronary intervention (PCI) treatment. A systematic literature search was conducted in Pubmed (from inception to September 27, 2014) and Embase (Ovid SP, from 1974 to September 29, 2014) to identify studies that compared the outcome of patients with AMI taking oral β-blockers with that of patients not taking after PCI. Systematic review and meta-analysis were performed with random-effects model or fixed-effects model. Ten observational studies with a total of 40,873 patients were included. Use of β-blockers was associated with a reduced risk of all-cause death (unadjusted relative risk 0.58, 95% confidential interval 0.48 to 0.71; adjusted hazard ratio 0.76, 95% confidential interval 0.62 to 0.94). The potential benefit of β-blockers in preventing all-cause death was not similar in all population but was restricted to those with reduced ejection fraction, with low use proportion of other secondary prevention drugs or with noneST-segment elevation myocardial infarction. The association between the use of β-blockers and improved survival rate was significant in ≤1-year follow-up duration. Rates of cardiac death, myocardial infarction, and heart failure readmission in patients using β-blockers were not significantly different from those in patients without b-blocker therapy. In conclusion, there is lack of evidence to support routine use of β-blockers in all patients with AMI who underwent PCI. Further trials are urgently needed to address the issue. [ABSTRACT FROM AUTHOR]